|
1) Hansson L, et al. Prospective randmized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press. 1992; 1: 113-9
|
|
|
|
2) Mochizuki S, et al. Valsartan in a Japanese population with hypertention and other cardiovascular disease: a randmised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007; 369: 1433-9
|
|
|
|
|
|
3) Dahlof B, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertention study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 993-1003
|
|
|
|
|
|
4) Pheffer MA, et al. Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349: 1893-906
|
|
|
|
|
|
5) Pheffer MA, et al. Effect of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362: 759-66
|
|
|
|
|
|
6) The ONTARGET investigators: Telmisartan, Ramipril, or Boyh in Patients at High Risk for Vascular Events. N Engl J Med. 2008; 358; 1547-59
|
|
|
|
|
|
7) Iwai M, et al. Delection of angiotensin II type2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation. 2005; 112: 1636-43
|
|
|
|
|
|
8) Neri Serneri GG, et al. Cardiac angiotensin II participates in coronary microvessel inflamation of unstable angina and strengthens the immunomediated component. Circ Res. 2004; 94: 1630-7
|
|
|
|
|
|
9) Kondo J, et al. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J. 2003; 146: E20
|
|
|
|
|
|
10) Habashi JP, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006; 312: 117-21
|
|
|
|
|
|
11) Verma S, et al. Angiotensin receptor blockers and myocardial infarction. Br Med J. 2004; 329: 1248-9
|
|
|
|
|